Navigation Links
Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
Date:12/12/2011

He also serves as co-director of the RNA Therapeutics Institute at the University of Massachusetts Medical School.  

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

For further information, please contact:


    Silence Therapeutics
    Thomas Christély/Max Herrmann
    +49-30-9489-2800 / +44(0)20-7491-6520
    t.christely@silence-therapeutics.com
    m.herrmann@silence-therapeutics.com

 

    Singer Capital Markets
    Shaun Dobson/Claes Spång
    +44(0)20-32057500
    shaun.dobson@singercm.com
    claes.spang@singercm.com

 

    M:Communications (Europe)
    Peter Laing / Emma Thompson
    +44(0)20-7920-2345 / +44(0)20-7920-2342
    healthcare@mcomgroup.com


'/>"/>
SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
2. Silence Therapeutics Provides Corporate and Development Update
3. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
6. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
7. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Achim Noack has been named global vice president ... position, Noack will assist Jerry Stoller, CEO and president ... and supervise global marketing management and implementation of new ... and experience in the crop protection industry,” says Jerry ... thinking will be a great asset for Stoller Group, ...
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
(Date:12/15/2014)... -- GlassesOff Inc. (OTCBB: GLSO) announced today the appointment of ... of the Company,s Board of Directors. Mr. ... CEO until its acquisition by Stanley Black ... as the inventor of the first Wi-Fi-based Active RFID ... RFID solutions focused on improving operational efficiency, safety and ...
Breaking Biology Technology:Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... developed by a University of Wisconsin-Madison Engineering professor could ... such devices as laptop computers and provide insights into ... This device will allow researchers to study for the ... on single electron transport in transistors. ...
... the first-ever Wisconsin Entrepreneurs Conference in Milwaukee last week, it ... what they were doing and what they planned to do. ... a plan to rid Lake Erie of the dreaded zebra ... quickly making it the scourge of the entire Great Lakes ...
... 29 Berbee Information Networks Corporation, a leading Midwest provider ... today that it has been selected by Microsoft as ... and Visual Studio .NET 2003 Launch. , , ... Express Center inMilwaukee, Wisconsin, Berbee will speak in depth ...
Cached Biology Technology:Cool Computers 2Cool Computers 3Entrepreneurial Spirit Infectious in Milwaukee 2Entrepreneurial Spirit Infectious in Milwaukee 3
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... cost of saving a teenage life? When it comes ... there,s no price tag. Parents with good intentions, however, ... not protecting their teens from the ticking timebomb of ... premium-quality medical supplies, has formed an exclusive partnership with ...
... bottle or finger sucking may hamper a child,s speech ... In a study that took place in Patagonia, Chile, ... an increased risk of speech disorders in preschool children. ... certain word sounds and to simplify their pronunciation. ...
... the key to new ways to fight cancer and ... role in regulating circadian rhythm, says Liheng Shi, a ... Circadian rhythm is the roughly 24-hour cycle of physiological ... He and colleagues have had their research, currently focusing ...
Cached Biology News:MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Infant sucking habits may affect how baby talks 2Texas A&M researchers find new mechanism for circadian rhythm 2
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Human DCIR/CLEC4A Phycoerythrin MAb (Clone 216110)...
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
Biology Products: